1European Medicines Agency. Regulation (EC) No 1902/2006 an amending regulation in which changes to the original text were in- troduced relating to decision procedures for the European Commis- sion[EB/OL], http://ec, europa, eu/health/files/eudralex/vol- 1/reg_2006_1902/reg_2006_1902_en.
2European Medicines Agency. Report to the European Commission: Companies and products that have benefited from any of the rewards and incentives in the paediatric regulation and the companies that have failed to comply with any of the obligations in this regulation covering the yem~ 2007 to 21309 [ EB/OL]. http://ec, europa, eu/ health/files/paediatrics/article_50_report2010.
3European Medicines Agency, Committee for Medicinal Products for HumanUse(CHMP). Concept Paper on Conduct of Pharmacovigi- lance for Medicines Used by Children [ EB/OL] . http:// www. ema. europa, eu/docs/en_GB/document_library/Scientific_ guideline/2009/O9/WC500003765.
4European Medicines Agency, Committee for Medicinal Products for HumanUse(CHMP). Guideline on Conduct of Pharmacovigilance for Medicines Used by the Paediatric Population [ EB/OL ]. ht- to ://www. tza. zov. au/docs/odf/eu~uide/ohvwo/23591005 en.
5DANIEL K B,BRIAN S,JESSICA M S,et al. Pediatric drug tri- als : safety and transparency [ J/OL]. Arch Pediatr Adolesc Med, 2009, 163 ( 12 ) : 1080-1086 [ 2011-03-24 ]. http://archpe- di. ama-assn, org/cgi/reprint/163/12/1080.
6Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: The Content and For- mat for Pediatric Use Supplements [ EB/OL ] . http:// www. fda. gov/downloads/Drugs/GuidanceComplianceRegulatory- Informatiorr/Guidances/ucm071957.
7Food and Drug Administration. In Proceedings of 105th Congress of the United States of America[ EB/OL]. http://www, fd& gov! downloads/RegulatoryInformation/Legislation/FederalFoodDru- gandCosmetieActFDCAct/SignificantAmendmentstotheFDCAct/ FDAMA/FullTextofFDAMAIaw/UCM089145.
8Food and Drug Administration. Regulations Requiring Manufac- turers to Assess the Safety and Effectiveness of New Drugs and Bi- ological Products in Pediatric Patients; Final Rule[ EB/OL]. ht- tp://www, fda. gov/ohrms/dockets/98fr/120298c.
9MARTIN W. The New Paediatric Regulation in the EU-Development, Implications and Comparison with US Experiences in Pae- diatric Drug Development [ EB/OL ] . Bonn Univ. of Bonn, 2007. http://www, dgrz. de/studiengang/pdf/master_watzl_m.
10Food and Drug Administration. In Proceedings of 107th Congress of the United States of America[ EB/OL]. http://www, fda. gov/ downloads/Drugs/DevelopmentApprovalProcess/DevelopmentRe- sources/UC M049874.
